Bromocriptine and the Clinical Spectrum of Parkinson's Disease

Richard J. Riopelle

ABSTRACT: As the direct agonist with the widest clinical use, bromocriptine provides a unique window into the clinical spectrum of Parkinson's disease. The efficacy of bromocriptine for therapy of de novo Parkinson's disease has recently been confirmed using a double-blind design with L-Dopa (Sinemet). Over a period of 5.5 months, bromocriptine was found to be as effective as L-Dopa in reducing the functional and neurological disability of Parkinson's disease. This study complements others and demonstrates a role for bromocriptine as de novo therapy. A longitudinal study comparing bromocriptine with L-Dopa is underway, but previous observations with bromocriptine suggest modest, transient beneficial effects with significantly less fluctuation of disability and less dyskinesia when used alone or in combination with L-Dopa. The transient benefits of bromocriptine on progressive disability suggest that both pre- and post-synaptic defects are eventually involved in Parkinson's disease. While agonists with improved efficacy and minimal side effects are required for symptomatic treatment of Parkinson's disease, strategies to protect pre- and post-synaptic neuron populations against progressive dysfunction must be developed.

Since its introduction to the therapeutic regimen of Parkinson's disease in 1974, bromocriptine has secured a position as adjuvant therapy to L-Dopa. Fluctuations in Parkinson's disease symptoms have been lessened by adjuvant therapy at least in part because addition of bromocriptine with its D-2 dopamine receptor agonist effects has permitted reduction of doses of L-Dopa.

The limited time span of L-Dopa effectiveness and the onset of unmodifiable motor and mental side effects of therapy in Parkinson's disease have been the impetus to delay therapy with L-Dopa until the failure of other therapeutic modalities had occurred. It is argued, however, that progressive disability is related only to progression of disease, and that the best response to L-Dopa will be seen with early therapy.

While these controversies persist, a pragmatic approach might be that introduction of therapy with L-Dopa should occur when disability of Parkinson's disease is interfering with work, recreation, or interpersonal relationships, and when other modalities used for de novo therapy no longer control the disability.

Experience with bromocriptine as de novo treatment of Parkinson's disease is limited to a few hundred patients. The consensus of investigators using bromocriptine as long-term de novo therapy suggests that, while less dyskinesia and less fluctuations in disability are observed, clinical effectiveness of the agonist is modest, transient, and often limited by dose-related side effects. To complement earlier clinical observations, the first phase of a long-term multicentre study comparing bromocriptine and L-Dopa (as Sinemet) as de novo therapy using a double-blind randomized design has recently been completed.

As the direct agonist with the widest clinical use, bromocriptine provides a unique window into the clinical spectrum of Parkinson's disease. One of the implications from studies of the efficacy of bromocriptine in the various stages of Parkinson's disease is...
that new strategies of therapy for Parkinson’s disease must be developed.

**METHODS**

**Study Design**

Patients with idiopathic Parkinson’s disease who had not been exposed previously to anti-Parkinson therapy (other than anticholinergics) were assigned randomly (intracentre) to the two treatment groups in seven centres. The study of twenty-three weeks’ duration was divided into three consecutive phases consisting of (i) a two-week baseline phase during which patients were assessed twice; (ii) a titration phase lasting a maximum of fifteen weeks during which medication dosage provided as identical capsules was incremented following assessment every two weeks until stable improvement or a maximum of 30 mg per day of bromocriptine or 300/75 mg of Sinemet (whichever came first) was achieved; (iii) a maintenance period of six weeks’ duration where the medication dosage was held constant.

For the first three weeks of treatment, daily dosages of bromocriptine and L-Dopa were 5 mg and 50 mg respectively. Stable improvement was defined as lack of further improve-

<table>
<thead>
<tr>
<th>Table 1: Demographics and results of therapy in 77 patients*</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
</tr>
<tr>
<td>number entered</td>
</tr>
<tr>
<td>number completing 23 weeks</td>
</tr>
<tr>
<td>sex: female/male</td>
</tr>
<tr>
<td>age (years)</td>
</tr>
<tr>
<td>clinical stage at entry**</td>
</tr>
<tr>
<td>I</td>
</tr>
<tr>
<td>II</td>
</tr>
<tr>
<td>III</td>
</tr>
<tr>
<td>IV</td>
</tr>
<tr>
<td>V</td>
</tr>
<tr>
<td>mean clinical stage</td>
</tr>
<tr>
<td>daily dose (mg) at week 23</td>
</tr>
<tr>
<td>previous/concomitant anticholinergics</td>
</tr>
</tbody>
</table>

Intragroup improvement % (week 0 vs week 23)*

- Hoehn and Yahr clinical stage 20% 16%
- Columbia University Scale — cardinal signs: tremor 59 63
  - rigidity 66 57
  - bradykinesia 49 47
- motor & posture: arising 65 47 (p=0.001)
  - posture 56 48
  - postural stability 61 54
  - gait 57 45
- Columbia University Scale — overall improvement: 61% 55%
- Northwestern University Disability Scale 38% 37%


** includes only those completing study

§ significant at p=0.0001 unless noted

**Analysis**

Parameters used to assess efficacy were the clinical status of Hoehn and Yahr,\(^3\) the Columbia University Scale,\(^4\) and the Northwestern University Disability Scale.\(^5\) Side effects of medications were reported at every visit, and the safety of the medications was monitored by periodic evaluation consisting of physical examination including vital signs, hematological and biochemical parameters, urinalysis, chest X-ray, and electrocardiogram.

All data were analyzed using the S.A.S. Package; the significance level for inferential tests was fixed at 1%.

**RESULTS**

The seven centres participating in the study entered eighty-one patients; forty-two patients were assigned to the bromocriptine group, and thirty-nine to the L-Dopa group. Four patients on bromocriptine dropped out of the study, leaving a total of seventy-seven patients (thirty-eight bromocriptine, thirty-nine L-Dopa) completing the twenty-three week trial.

Table 1 summarizes the patient demographics and results of treatment in the two groups at twenty-three weeks. At the onset of the study, patient demographics were similar in the two groups, and the entry clinical stage of the patients completing the twenty-three week study showed no significant differences. The mean of the entry clinical stage was 2.66 for the bromocriptine group and 2.33 for the L-Dopa group. No statistically significant difference was found between the two groups for any parameter of the Columbia University Scale or the Northwestern University Disability Scale (NUDS) at entry.

At the end of twenty-three weeks, the thirty-eight bromocriptine patients were taking 26 ± 1.2 mg (mean ± s.e.m.), and the thirty-nine L-Dopa patients were taking a dose of 262.8 ± 10 mg of L-Dopa (in Sinemet).

The four patients who dropped out of the study were in the bromocriptine group. As a group, these patients left the study before the dose was incremented to 10 mg per day at the end of the first three weeks of the fifteen-week titration phase.

When comparisons between scores at week 0 and the end of the study were made, improvements in the clinical stage of patients was 20% for bromocriptine and 16% for L-Dopa. Overall improvement on the Columbia University Scale was 61% and 55% for bromocriptine and L-Dopa respectively, while in the NUDS, overall improvement was 38% and 37% respectively. Within each group there was a statistically significant improvement in all parameters of the two multiparameter rating scales. The level of significance of the observations summarized in Table 1 within the two groups was high. No significant differences were found between the two groups for clinical stage, overall assessments with the Columbia University Scale and NUDS, or cardinal signs as scored using the Columbia University Scale.

For the seventy-seven patients completing the twenty-three weeks of the study, dyskinesias and fluctuations in disability were absent, side effects were tolerable, and laboratory assessments did not necessitate discontinuation.
Bromocriptine in Early Parkinson’s Disease

While the present study complements and extends observations on the efficacy of bromocriptine in de novo Parkinson’s disease, direct comparison with other studies is tenuous at this time. In general terms, however, and in agreement with numerous observations, bromocriptine has been shown to be an effective anti-Parkinson agent. The data reported here are derived from the first large study to compare the efficacy and tolerance of bromocriptine with L-Dopa in a double-blind fashion in patients who have not been exposed previously to dopaminergic agents. Over a time frame of twenty-three weeks, bromocriptine at a mean dose of 26.1 mg was as effective as L-Dopa at a mean dose of 262.8 mg in improving clinical stage and the neurological and functional disabilities of Parkinson’s disease. The doses of bromocriptine and L-Dopa chosen for the present study reflected current usage of the direct agonist, the trend to lower doses of L-Dopa (with decarboxylase inhibitors), and a previously suggested equipotent milligram dose ratio of 1 to 10.\(^:\text{5,6}\)

Previously reported studies of bromocriptine in de novo patients have not been designed to compare in a blinded fashion one agent with the best available alternative. Some of these studies have concentrated on long-term efficacy of the direct agonist, and some have compared in an unblinded design the effects of bromocriptine with doses of L-Dopa that were usually higher than those used in the present study.

Table 2 denotes data from de novo studies of bromocriptine that could be analyzed in such a way as to facilitate comparison with the short-term results of the present study.\(^:\text{5,6,7,8,9,10,11}\)

The present study and six previous de novo studies demonstrate the overall efficacy of bromocriptine as a de novo anti-Parkinson agent. When compared in a double-blind design with L-Dopa at milligram dose ratios of approximately 1:10, bromocriptine and L-Dopa are equipotent, at least for periods up to approximately six months in patients with moderate disability.

On the basis of studies with bromocriptine and L-Dopa in de novo Parkinson’s disease, Rinne\(^:\text{12}\) has concluded that a combination of L-Dopa and bromocriptine provides the best control of Parkinson’s disease disability with less fluctuation and dyskinesia in long-term follow-up. The present study and the six earlier investigations referred to here would suggest that, for moderate Parkinson’s disease, bromocriptine can provide adequate control until such time that progressive clinical disability requires addition of L-Dopa to the therapeutic regimen.

The Problem of Progressive Disability in Parkinson’s Disease

Continuing analysis of patients entered in the present study which has now entered the open label phase will permit assessment of long-term efficacy of bromocriptine in Parkinson’s disease. However, published data on the long-term efficacy of this agonist do not provide cause for optimism. As summarized in Table 3, Rinne\(^:\text{12}\) reported only 15% improvement on the Columbia University Scale in twenty-one patients after thirty-six months on the drug. At twelve months, Lees and Stern\(^:\text{13}\) observed that 44% of patients did not achieve 25% reduction in symptoms, while Rascol et al\(^:\text{14}\) observed 27% improvement at twelve months in twenty-nine patients on a mean dose of 54.7 mg. At the end of thirty months, Grimes and Delgado\(^:\text{8}\) were able to adequately control Parkinson disability in only three patients. Similar data have been reported by Hardie et al\(^:\text{15}\) at sixty months. Alternatively, at the end of twenty-four months, Teychenne et al\(^:\text{10}\) witnessed 31% improvement in twelve patients with no significant change in disability at six, twelve, eighteen, and twenty-four months, even though the mean dose of bromocriptine increased from 11.7 mg at six months to 14 mg at twenty-four months.

### Table 2: Short-term results of bromocriptine therapy in de novo Parkinson’s disease

<table>
<thead>
<tr>
<th>Author</th>
<th>Mean dose (mg)</th>
<th>Time (mos.)</th>
<th>No.</th>
<th>Stage</th>
<th>% Improvement</th>
<th>Rating Scale</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rinne &amp; Marttila(^:\text{6})</td>
<td>30</td>
<td>5</td>
<td>23</td>
<td>3.0</td>
<td>34</td>
<td>cardinal signs*</td>
</tr>
<tr>
<td>Staal-Schreinemachers et al(^:\text{11})</td>
<td>15</td>
<td>6</td>
<td>10</td>
<td>1.9</td>
<td>25</td>
<td>cardinal signs</td>
</tr>
<tr>
<td>Devathasan et al(^:\text{7})</td>
<td>10</td>
<td>6</td>
<td>10</td>
<td>4.5</td>
<td>59</td>
<td>cardinal signs</td>
</tr>
<tr>
<td>Grimes &amp; Delgado(^:\text{8})</td>
<td>13.2**</td>
<td>6</td>
<td>20</td>
<td>2</td>
<td>32+</td>
<td>cardinal signs</td>
</tr>
<tr>
<td>Olanov &amp; Alberts(^:\text{9})</td>
<td>14.7</td>
<td>5.3</td>
<td>9</td>
<td>3</td>
<td>43.3</td>
<td>cardinal signs</td>
</tr>
<tr>
<td>Teychenne et al(^:\text{10})</td>
<td>11.7</td>
<td>12</td>
<td>6</td>
<td>2.7</td>
<td>31.1</td>
<td>cardinal signs</td>
</tr>
<tr>
<td>Riopelle et al (1987)(^:\ddagger)</td>
<td>26.1</td>
<td>5.5</td>
<td>38</td>
<td>2.7</td>
<td>61</td>
<td>cardinal signs</td>
</tr>
</tbody>
</table>

\(^:\ddagger\) clinical stage of Hoehn and Yahr
\(^*\) cardinal signs: tremor, rigidity, bradykinesia
\(^**\) approximate maximum based on increment of 1.25 mg/week up to 30 mg/day
\(^+\) initial peak effect

### Table 3: Long-term results of bromocriptine in de novo Parkinson’s disease

<table>
<thead>
<tr>
<th>Author</th>
<th>Mean Dose (mg)</th>
<th>Time (mos.)</th>
<th>No. of Patients</th>
<th>Stage</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rinne(^:\text{12})</td>
<td>28</td>
<td>36</td>
<td>21</td>
<td>2.8</td>
<td>15% improvement on Columbia scale</td>
</tr>
<tr>
<td>Rascol et al(^:\text{14})</td>
<td>53.7</td>
<td>12</td>
<td>29</td>
<td>1.9</td>
<td>27% improvement using author’s grading system</td>
</tr>
<tr>
<td>Teychenne et al(^:\text{10})</td>
<td>14</td>
<td>24</td>
<td>12</td>
<td>2.7</td>
<td>31% improvement in cardinal signs</td>
</tr>
<tr>
<td>Grimes &amp; Delgado(^:\text{8})</td>
<td>13.2</td>
<td>30</td>
<td>13</td>
<td>2</td>
<td>23% taking bromocriptine alone</td>
</tr>
<tr>
<td>Lees &amp; Stern(^:\text{13})</td>
<td>40</td>
<td>12</td>
<td>50</td>
<td>2.3</td>
<td>44% did not achieve 25% improvement; 18% showed sustained benefit</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Rating Scale</th>
</tr>
</thead>
<tbody>
<tr>
<td>cardinal signs*</td>
</tr>
<tr>
<td>cardinal signs</td>
</tr>
<tr>
<td>cardinal signs</td>
</tr>
<tr>
<td>cardinal signs</td>
</tr>
<tr>
<td>cardinal signs</td>
</tr>
<tr>
<td>cardinal signs</td>
</tr>
</tbody>
</table>
Published data suggest that bromocriptine, when used as adjuvant therapy with L-Dopa in de novo Parkinson’s disease patients,12 or when added to L-Dopa therapy as fluctuations and dyskinesias appear, reduces these side effects and probably extends the period of effectiveness of therapy. De novo studies with the agonist as the only therapy for Parkinson’s disease for periods greater than one to two years8,10,12,14 suggest that, while the appearance of fluctuations and dyskinesias is significantly less than with L-Dopa therapy, anti-Parkinson effects are modest at best and are not sustained. Thus, a combination of bromocriptine and L-Dopa, as suggested by Rinne,12 appears to be indicated to maximize efficacy of therapy while minimizing side effects.

The limited time span of L-Dopa effectiveness and the appearance of unmodifiable side effects of this therapy can likely be explained in part by progressive loss of nigrostriatal decarboxylase activity. Elucidation of mechanisms of MPTP toxicity have contributed to suggestions that the MAO-B system of striatal glia and the avid monoamine reuptake system of the nigrostriatal projection might provide a setting in which dopamine oxidation with free radical generation could set in place a nigrostriatal autotoxic mechanism that might accelerate disease by further compromise of the pre-synaptic projection.16-22 However, the suggestion that L-Dopa therapy contributes to the progressive disability of Parkinson’s disease is controversial. Markham and Diamond2 have presented data to suggest that disease severity and not duration of L-Dopa therapy determines disability and the appearance of unmodifiable side effects of treatment. These conclusions are supported by the observations of MPTP-exposed patients with Parkinsonism.24 Muetterties25 has argued that the best response to L-Dopa will be seen with early therapy, while Hoehn26 has observed that postponing treatment increases the incidence of non-responsiveness to available drugs.

The observation that the direct agonist bromocriptine has only transient beneficial influence on the progressive disability of late stage Parkinson’s disease argues that progressive loss of pre-synaptic nigrostriatal influence cannot explain completely the features of advanced treated disease. The failure of post-synaptic striatal systems could be implicated as a partial explanation for this non-responsiveness to therapy. A gradual alteration or loss of a D-2 dopamine receptor could explain in part the progressive loss of efficacy of L-Dopa and the failure of the D-2 receptor agonists to effectively replace L-Dopa in late stage disease. The modest influence of drug holidays27,28 and the failure of repeated drug withdrawal to restore responsiveness to therapy would suggest that D-2 receptor down regulation is likely playing only a small role in non-responsiveness. These clinical observations in late stage disease are suggestive of a loss of post-synaptic D-2 receptor-bearing neurons. In patients who are manifesting fluctuations in disability on L-Dopa therapy, the response to administration of apomorphine indicates that dopamine receptor is available and suggests that the “off” period is a supply-side problem.29 However, the response of these patients to pyridostigmine would suggest that striatal cholinergic synaptic mechanisms may be hypersensitive.29 These observations and the findings of some groups that choline acetyltransferase (ChAT) levels in striatum are decreased30,31 or unchanged32 in Parkinson’s disease could suggest a drop-out of striatal post-synaptic cholinergic neurons in late stage disease which might explain loss of efficacy of anti-Parkinson therapy and the clinical findings of suspected cholinergic hypersensitivity. The intriguing observations that loss of responsiveness to therapy in Parkinson’s disease is frequently associated with the appearance of dementia, and that dementia is commonly associated with the disease,33,34 might argue that these groups of patients suffer from a diffuse forebrain cholinergic disturbance.

Emerging concepts of trans-synaptic neuronal influence may provide partial explanation for the loss of response to treatment due to loss of post-synaptic neuronal populations. A declining pre-synaptic nigrostriatal input might result in loss of trans-synaptic trophic influence and/or reduced modulation of selective pressures on post-synaptic striatal neurons by the large cortical excitatory amino acid input (glu/asp),35 endogenous excitotoxins, or Ca + + fluxes. At this point, observations39,30,31,32 suggesting a drop-out of striatal post-synaptic cholinergic neurons and/or their extensive extrastriosomal neuropil36 requires confirmation by careful morphometric analysis. Regional neurotransmitter receptor and neurotransmitter-specific enzyme quantification may not provide a sensitive indicator of the integrity of individual post-synaptic neurons, some of which may be degenerating because of loss of trans-synaptic influence, and some of which may be responding transiently to denervation by up-regulation responses in the same time frame.

If, as is suggested for L-Dopa, the price of a highly efficacious symptomatic treatment of Parkinson’s disease disability is the development of side effects such as fluctuations in disability and dyskinesias, improved long-term symptomatic therapy may prove to be difficult to achieve. However, since disease severity appears to be a major factor in the development of side effects, protection of the integrity of remaining nigral neurons and post-synaptic D-2 receptor-bearing neuron populations should be important goals of future studies. In this regard, pharmaceuticals active on MAO-B systems, monoamine reuptake inhibitors, and free-radical scavengers might have symptomatic and/or protective effects in Parkinson’s disease. Additionally, neurotrophic factors may have a role in protection of pre- and post-synaptic neurons. The recent observations that striatal cholinergic neurons bear high affinity Nerve Growth Factor (NGF) receptors37,38 and respond to pharmacological doses of the protein39 provide justification for studies of the role of NGF in MPTP models of Parkinsonism.

ACKNOWLEDGEMENTS

Stephanie McCaughey produced the manuscript. Some of the studies referred to in the manuscript were supported by a MRC Canada grant to the author. Sandoz (Canada) supported the double-blind study.

REFERENCES